Source-grounded facts extracted from Nurix Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nurix Therapeutics, Inc. entered into Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $700.0 million (effective 2026-06-06).
“On June 6, 2026, Nurix Therapeutics, Inc. (" Nurix ") entered into a License and Collaboration Agreement (the " Collaboration Agreement "), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, " Roche ")”
Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2026-05-15 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 72,458,920 6,895,394 573,204 3,819,495”
Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2026 at the 2026-05-15 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 83,555,977 166,391 24,645 —”
Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2026-05-15 meeting.
“Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 63,592,948 16,334,570 3,819,495 Roger Dansey, M.D. 79,607,489 320,029 3,819,495 Paul M. Silva 59,298,612 20,628,906 3,819,495”
Nurix Therapeutics, Inc. reported the fiscal quarter ended February 28, 2026 results: revenue $6.3 million.
“Revenue for the three months ended February 28, 2026, was $6.3 million”
Anil Kapur was appointed as Director at Nurix Therapeutics, Inc..
“On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.”
Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).
“On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).”
Nurix Therapeutics, Inc. reported financial results for first quarter ended February 29, 2024.
“Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.”
Nurix Therapeutics, Inc. reported financial results for the fiscal quarter and fiscal year ended November 30, 2023.
“today reported financial results for the fiscal quarter and fiscal year ended November 30, 2023, and provided a corporate update.”
Nurix Therapeutics, Inc. reported fiscal quarter ended August 31, 2023 results: revenue $18.5 million, net income $37.0 million, or ($0.68) per shar, EPS $(0.68).
“Revenue for the three months ended August 31, 2023, was $18.5 million compared to $10.8 million for the three months ended August 31, 2022. The increase was primarily due to a higher percentage of completion of performance obligations and an increase in the value of milestones achieved in the current period. During the three months ended August 31, 2023, Nurix achieved research milestones under its collaborations with Gilead and Sanofi totaling $6.0 million and $2.0 million, respectively. Research and development expenses for the three months ended August 31, 2023, were $47.9 million compared to $47.8 million for the three months ended August 31, 2022. There was an increase in clinical costs as Nurix continued its clinical trial programs and ongoing patient enrollment, primarily offset by a decrease in research related costs and in contract manufacturing. There was also an increase in facility and other costs primarily driven by additional investments in information technology and leas”
Nurix Therapeutics, Inc. entered into Collaboration Agreement with Seagen Inc. valued at $60 million (effective 2023-09-06).
“On September 6, 2023, Nurix Therapeutics, Inc. (“Nurix” or the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Seagen Inc. (“Seagen”)”
Nurix Therapeutics, Inc. reported the fiscal quarter ended May 31, 2023 results: revenue $30.7 million.
“Revenue for the three months ended May 31, 2023, was $30.7 million compared to $11.4 million for the three months ended May 31, 2022.”
Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2023-05-04 meeting.
“Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 19,907,448 12,499,830 1,644,715 5,185,918 The stockholders approved”
Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2023. at the 2023-05-04 meeting.
“Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Abstentions Broker Non-Votes 39,212,140 10,575 15,196 — The stockholders ratified the appointment”
Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors: Arthur T. Sands, M.D., Ph.D., Lori A. Kunkel, M.D., Paul M. Silva, each to serve a three-year term expiring at the 2026 annual meeting. at the 2023-05-04 meeting.
“Proposal 1. Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 33,080,351 971,642 5,185,918 Lori A. Kunkel, M.D. 29,782,567 4,269,426 5,185,918 Paul M. Silva 29,337,363 4,714,630 5,185,918 Each of the three nominees for director was elected”
Nurix Therapeutics, Inc. reported financial results for first quarter ended February 28, 2023.
“On April 13, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2023.”
Stefani A. Wolff resigned as Chief Operating Officer and Executive Vice President of Product Development at Nurix Therapeutics, Inc..
“On April 5, 2023, Stefani A. Wolff notified Nurix Therapeutics, Inc. (“Nurix”) of her decision to resign from her position as Chief Operating Officer and Executive Vice President of Product Development of Nurix, effective May 2, 2023.”
Nurix Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended November 30, 2022.
“On February 9, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2022.”
Nurix Therapeutics, Inc.: Amended and restated bylaws to update stockholder meeting procedures, advance notice requirements, universal proxy rules, and other provisions to conform to DGCL amendments and SEC universal proxy rules (effective 2022-12-15).
“On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Nurix Therapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.”
Edward C. Saltzman was appointed as director at Nurix Therapeutics, Inc..
“On September 12, 2022, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Edward C. Saltzman to serve as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”) and the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.”
Clay B. Siegall resigned as Class II member of the Board at Nurix Therapeutics, Inc..
“On May 15, 2022, Clay B. Siegall, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. of his resignation as a Class II member of the Board and as a member of the Board’s Compensation Committee and Development Advisory Committee, effective immediately.”
Jeffrey K. Tong resigned as Class II Director at Nurix Therapeutics, Inc..
“On March 2, 2022, Jeffrey K. Tong, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that he will resign as a Class II member of the Board and as a member of the Board’s Audit Committee and Compensation Committee, effective on the date of the Company’s 2022 Annual Meeting of Stockholders (the “Resignation”).”
Paul M. Silva was appointed as Director at Nurix Therapeutics, Inc..
“appointed each of Judith A. Reinsdorf and Paul M. Silva to serve as a director of the Company, effective October 1, 2021”
Judith A. Reinsdorf was appointed as Director at Nurix Therapeutics, Inc..
“appointed each of Judith A. Reinsdorf and Paul M. Silva to serve as a director of the Company, effective October 1, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.